Improving Pain Management in Patients With Nonhematologic Cancer
RATIONALE: A pain assessment and management system for people with cancer may help doctors accurately assess and plan more effective pain treatment for patients who have cancer.
PURPOSE: Clinical trial to determine the effectiveness of a pain assessment and management system in improving pain management in patients who have nonhematologic cancer.
|Pain Unspecified Adult Solid Tumor, Protocol Specific||Procedure: pain therapy|
|Official Title:||Improving Pain Management in Cancer Care|
|Study Start Date:||March 2002|
|Study Completion Date:||April 2003|
- Develop and test a pain assessment and management system for people with cancer (PAMS-PC).
- Obtain feedback from patients with non-hematologic malignancies on the proposed features of the system and its usability and effectiveness.
OUTLINE: This is a multicenter study. The study contains 3 parts. Patients in part II are assigned to 1 of 2 assessment groups.
- Part I: Patients participate in a focus interview by telephone over approximately 45 minutes. The interview includes discussion of beliefs and concerns regarding pain and its management, strategies used by the patient for managing pain, the features of the proposed pain assessment and management system for people with cancer (PAMS-PC), and reactions of the patients to each proposed component of the system.
- Group A: Patients participate in an assessment session over approximately 90 minutes, comprising completion of a questionnaire followed by use of a test version of the PAMS-PC.
- Group B: Patients use the PAMS-PC first followed by completion of the questionnaire.
Thirty patients are then randomly selected from the 2 groups to repeat use of the PAMS-PC 3 hours after the initial assessment.
- Part III: Patients participate in a patient acceptance test over 30-60 minutes, in which patients test the demo version of the system, complete an evaluation questionnaire, and provide feedback by telephone.
PROJECTED ACCRUAL: A total of 180 patients (10 for part I, 150 (75 per group) for part II, and 20 for part III) will be accrued for this study.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00036829
|United States, Massachusetts|
|Newton, Massachusetts, United States, 02464-1594|
|Study Chair:||Michael Sean Davis, PhD||Inflexxion, Inc.|